{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:24:02Z","timestamp":1792009442325,"version":"4.4.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jaci.2020.07.001","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T07:06:37Z","timestamp":1599203197000},"page":"518-534.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":250,"title":["The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection"],"prefix":"10.1016","volume":"146","author":[{"given":"Ana","family":"Copaescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Smibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Trubiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2020.07.001_bib1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2020.07.001_bib2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2020.07.001_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib4","doi-asserted-by":"crossref","unstructured":"Herold T, Jurinovic V, Arnreich C, Hellmuth J, von Bergwelt-Baildon M, Klein M, et\u00a0al. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients [published online ahead of print April 10, 2020]. medRxiv. https:\/\/doi.org\/10.1101\/2020.04.01.20047381.","DOI":"10.1101\/2020.04.01.20047381"},{"key":"10.1016\/j.jaci.2020.07.001_bib5","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunologic features in severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jaci.2020.07.001_bib6","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2020.07.001_bib7","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib8","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(20)31094-1","article-title":"Hyperinflammatory shock in children during COVID-19 pandemic","volume":"395","author":"Riphagen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2020.07.001_bib9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00281-017-0639-8","article-title":"Cytokine storm and sepsis disease pathogenesis","volume":"39","author":"Chousterman","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaci.2020.07.001_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.jaci.2020.07.001_bib11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.virol.2007.04.009","article-title":"Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB","volume":"365","author":"Zhang","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.jaci.2020.07.001_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jmv.20255","article-title":"An interferon-gamma-related cytokine storm in SARS patients","volume":"75","author":"Huang","year":"2005","journal-title":"J Med Virol"},{"key":"10.1016\/j.jaci.2020.07.001_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"Channappanavar","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaci.2020.07.001_bib14","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza A\u00a0(H5N1) is associated with high viral load and hypercytokinemia","volume":"12","author":"de Jong","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3947\/ic.2016.48.2.118","article-title":"Clinical presentation and outcomes of Middle East respiratory syndrome in the Republic of Korea","volume":"48","author":"Choi","year":"2016","journal-title":"Infect Chemother"},{"key":"10.1016\/j.jaci.2020.07.001_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijid.2014.09.003","article-title":"Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia","volume":"29","author":"Saad","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jaci.2020.07.001_bib17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.idc.2019.08.001","article-title":"The Middle\u00a0East\u00a0respiratory syndrome (MERS)","volume":"33","author":"Azhar","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jaci.2020.07.001_bib18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmi.2020.03.026","article-title":"COVID-19, SARS and MERS: are they closely related?","volume":"26","author":"Petrosillo","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaci.2020.07.001_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.jaci.2020.07.001_bib20","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.40071","article-title":"Review: cytokine storm syndrome: looking toward the precision medicine era","volume":"69","author":"Behrens","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2020.07.001_bib21","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.bbmt.2009.11.014","article-title":"Histiocytic disorders: recent insights into pathophysiology and practical guidelines","volume":"16","author":"Filipovich","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2020.07.001_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.berh.2014.03.002","article-title":"Macrophage activation syndrome and cytokine-directed therapies","volume":"28","author":"Schulert","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jaci.2020.07.001_bib23","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/cc10073","article-title":"Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A\u00a0(H1N1) infection","volume":"15","author":"Beutel","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.jaci.2020.07.001_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","article-title":"Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies","volume":"66","author":"Schulert","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2020.07.001_bib26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/infdis\/jiv550","article-title":"Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza","volume":"213","author":"Schulert","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaci.2020.07.001_bib28","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa2006100","article-title":"Spread of SARS-CoV-2 in the Icelandic population","volume":"382","author":"Gudbjartsson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/jpids\/piaa061","article-title":"COVID-19 associated pediatric multi-system inflammatory syndrome","volume":"9","author":"Deza Leon","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.jaci.2020.07.001_bib30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1542\/hpeds.2020-0123","article-title":"COVID-19 and Kawasaki disease: novel virus and novel case","volume":"10","author":"Jones","year":"2020","journal-title":"Hosp Pediatr"},{"key":"10.1016\/j.jaci.2020.07.001_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10408363.2013.764490","article-title":"Biomarkers of sepsis","volume":"50","author":"Faix","year":"2013","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.jaci.2020.07.001_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5492\/wjccm.v8.i5.74","article-title":"Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: the role of inflammatory biomarkers","volume":"8","author":"Chalmers","year":"2019","journal-title":"World J Crit Care Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41577-020-0346-x","article-title":"Dysregulation of type I interferon responses in COVID-19","volume":"20","author":"Acharya","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2020.07.001_bib34","doi-asserted-by":"crossref","unstructured":"Chu H, Chan JF, Wang Y, Yuen TT, Chai Y, Hou Y, et\u00a0al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex\u00a0vivo study with implications for the pathogenesis of COVID-19 [published online ahead of print April 9, 2020]. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa410.","DOI":"10.1093\/cid\/ciaa410"},{"key":"10.1016\/j.jaci.2020.07.001_bib35","doi-asserted-by":"crossref","unstructured":"O\u2019Brien TR, Thomas DL, Jackson SS, Prokunina-Olsson L, Donnelly RP, Hartmann R. Weak Induction of interferon expression by SARS-CoV-2 supports clinical trials of interferon lambda to treat early COVID-19 [published online ahead of print April 17, 2020]. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa453.","DOI":"10.1093\/cid\/ciaa453"},{"key":"10.1016\/j.jaci.2020.07.001_bib36","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2020.07.001_bib37","doi-asserted-by":"crossref","unstructured":"Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages [published online ahead of print May 6, 2020]. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/s41577-020-0331-4.","DOI":"10.1038\/s41577-020-0331-4"},{"key":"10.1016\/j.jaci.2020.07.001_bib38","doi-asserted-by":"crossref","unstructured":"Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et\u00a0al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID 19 patients [published online ahead of print March 13, 2020]. Natl Sci Rev. https:\/\/doi.org\/10.1093\/nsr\/nwaa041.","DOI":"10.1093\/nsr\/nwaa041"},{"key":"10.1016\/j.jaci.2020.07.001_bib39","doi-asserted-by":"crossref","unstructured":"Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, et\u00a0al. COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome [published online ahead of print March 26, 2020]. medRxiv. https:\/\/doi.org\/10.1101\/2020.03.24.20042655.","DOI":"10.1101\/2020.03.24.20042655"},{"key":"10.1016\/j.jaci.2020.07.001_bib40","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3389\/fimmu.2017.01454","article-title":"Bruton\u2019s tyrosine kinase: an emerging key player in innate immunity","volume":"8","author":"Weber","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2020.07.001_bib41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41421-020-0168-9","article-title":"Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing","volume":"6","author":"Wen","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.jaci.2020.07.001_bib42","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.001_bib43","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib44","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaci.2020.07.001_bib45","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: a storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2020.07.001_bib46","doi-asserted-by":"crossref","unstructured":"Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et\u00a0al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) [published online ahead of print May 1, 2020]. medRxiv. https:\/\/doi.org\/10.3389\/fimmu.2020.00827.","DOI":"10.3389\/fimmu.2020.00827"},{"key":"10.1016\/j.jaci.2020.07.001_bib47","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000505099","article-title":"Interleukin-6: a masterplayer in the cytokine network","volume":"98","author":"Uciechowski","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.jaci.2020.07.001_bib49","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1084\/jem.20190344","article-title":"Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses","volume":"216","author":"Spencer","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib50","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jaci.2020.07.001_bib51","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1128\/JVI.01601-08","article-title":"Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor","volume":"83","author":"Adam","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jaci.2020.07.001_bib52","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-3083.2006.01750.x","article-title":"Interleukin-6 trans-signalling in chronic inflammation and cancer","volume":"63","author":"Scheller","year":"2006","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jaci.2020.07.001_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111736","article-title":"ADAM17 activity and IL-6 trans-signaling in inflammation and cancer","volume":"11","author":"Schumacher","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaci.2020.07.001_bib54","doi-asserted-by":"crossref","unstructured":"Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et\u00a0al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) [published online ahead of print February 12, 2020]. medRxiv. https:\/\/doi.org\/10.1101\/2020.02.10.20021832.","DOI":"10.1101\/2020.02.10.20021832"},{"key":"10.1016\/j.jaci.2020.07.001_bib55","unstructured":"Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et\u00a0al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients [published online ahead of print March 3, 2020]. medRxiv. https:\/\/doi.org\/10.1101\/2020.02.29.2002952."},{"key":"10.1016\/j.jaci.2020.07.001_bib56","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/jmv.25770","article-title":"Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19","volume":"92","author":"Gao","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.jaci.2020.07.001_bib57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","volume":"146","author":"Li","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.07.001_bib58","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/CCM.0b013e31819def97","article-title":"The sequential organ failure assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation","volume":"37","author":"Jones","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib59","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1128\/IAI.72.8.4410-4415.2004","article-title":"Analysis of serum cytokines in patients with severe acute respiratory syndrome","volume":"72","author":"Zhang","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaci.2020.07.001_bib60","doi-asserted-by":"crossref","unstructured":"Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China [published online ahead of print March 16, 2020]. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa272.","DOI":"10.1093\/cid\/ciaa272"},{"key":"10.1016\/j.jaci.2020.07.001_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033095","article-title":"Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma","volume":"7","author":"Gouel-Cheron","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2020.07.001_bib62","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00011-009-0003-0","article-title":"Serial cytokine levels in patients with severe sepsis","volume":"58","author":"Wu","year":"2009","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jaci.2020.07.001_bib63","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/archinte.167.15.1655","article-title":"Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) study","volume":"167","author":"Kellum","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib64","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.diagmicrobio.2012.12.011","article-title":"Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis","volume":"75","author":"Jekarl","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jaci.2020.07.001_bib65","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00268-008-9896-y","article-title":"Early serum procalcitonin, interleukin-6, and 24-hour lactate clearance: useful indicators of\u00a0septic infections in severely traumatized patients","volume":"33","author":"Billeter","year":"2009","journal-title":"World J Surg"},{"key":"10.1016\/j.jaci.2020.07.001_bib66","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1399-6576.2008.01801.x","article-title":"The early IL-6 and IL-10 response in trauma is correlated with injury severity and mortality","volume":"53","author":"Stensballe","year":"2009","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jaci.2020.07.001_bib67","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/shk.0b013e318123e64e","article-title":"Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma","volume":"28","author":"Maier","year":"2007","journal-title":"Shock"},{"key":"10.1016\/j.jaci.2020.07.001_bib68","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1186\/s12879-019-4618-7","article-title":"Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions","volume":"19","author":"Song","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jaci.2020.07.001_bib69","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3109\/00365548.2011.600325","article-title":"Early detection of severe sepsis in the emergency room: diagnostic value of plasma C-reactive protein, procalcitonin, and interleukin-6","volume":"43","author":"Uusitalo-Seppala","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jaci.2020.07.001_bib70","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/SHK.0000000000000616","article-title":"Interleukin-6 levels act as a diagnostic marker for infection and a prognostic marker in patients with organ dysfunction in intensive care units","volume":"46","author":"Takahashi","year":"2016","journal-title":"Shock"},{"key":"10.1016\/j.jaci.2020.07.001_bib71","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/ajrccm.164.3.2009052","article-title":"Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis","volume":"164","author":"Harbarth","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib72","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cyto.2016.08.033","article-title":"Role of interleukin-6 to differentiate sepsis from non-infectious systemic inflammatory response syndrome","volume":"88","author":"Ma","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2020.07.001_bib73","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1007\/s00134-002-1416-1","article-title":"Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis","volume":"28","author":"Pettila","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib74","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcrc.2016.01.002","article-title":"The diagnostic ability of procalcitonin and interleukin-6 to differentiate infectious from noninfectious systemic inflammatory response syndrome and to predict mortality","volume":"33","author":"Mat-Nor","year":"2016","journal-title":"J Crit Care"},{"key":"10.1016\/j.jaci.2020.07.001_bib75","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.imbio.2016.03.005","article-title":"Influence of gender on systemic IL-6 levels, complication rates and outcome after major trauma","volume":"221","author":"Mors","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.jaci.2020.07.001_bib76","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.001_bib78","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clim.2016.06.014","article-title":"Plasma IFN-gamma and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells","volume":"169","author":"Klaver","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2020.07.001_bib79","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib80","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","article-title":"IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review","volume":"29","author":"Ogata","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaci.2020.07.001_bib82","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jaci.2020.07.001_bib83","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2020.07.001_bib84","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.001_bib85","unstructured":"Roumier M, Paule R, Groh M, Vall\u00e9e A, Ackermann F. Interleukin-6 blockade for severe COVID-19 [published online ahead of print April 22, 2020]. medRxiv."},{"key":"10.1016\/j.jaci.2020.07.001_bib86","doi-asserted-by":"crossref","unstructured":"Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, et\u00a0al. Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes [published online ahead of print June 15, 2020]. Chest. https:\/\/doi.org\/10.1016\/j.chest.2020.06.006.","DOI":"10.1016\/j.chest.2020.06.006"},{"key":"10.1016\/j.jaci.2020.07.001_bib88","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","article-title":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome","volume":"136","author":"Wong","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2020.07.001_bib89","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.rdc.2004.01.005","article-title":"The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis","volume":"30","author":"Cohen","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaci.2020.07.001_bib91","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10875-017-0439-x","article-title":"A personalized diagnostic and treatment approach for macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in adults","volume":"37","author":"Kumar","year":"2017","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2020.07.001_bib92","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaci.2020.07.001_bib93","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1073\/pnas.0711241105","article-title":"Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry","volume":"105","author":"Haga","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2020.07.001_bib94","first-page":"60","article-title":"Cosentyx (Secukinumab): first IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis","volume":"9","author":"Fala","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jaci.2020.07.001_bib95","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib","volume":"53","author":"Wu","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jaci.2020.07.001_bib97","doi-asserted-by":"crossref","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2020.07.001_bib99","doi-asserted-by":"crossref","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et\u00a0al. Remdesivir for the treatment of Covid-19\u2014preliminary report [published online ahead of print May 22, 2020]. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2007764.","DOI":"10.1056\/NEJMoa2007764"},{"key":"10.1016\/j.jaci.2020.07.001_bib101","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.07.001_bib102","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.canlet.2019.02.029","article-title":"STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity","volume":"450","author":"Pei","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jaci.2020.07.001_bib103","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1312625","article-title":"Activated\u00a0STING in a vascular and pulmonary syndrome","volume":"371","author":"Liu","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2020.07.001_bib104","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2020.07.001_bib105","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41577-020-0320-7","article-title":"Complement as a target in COVID-19?","volume":"20","author":"Risitano","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2020.07.001_bib106","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/CIRCULATIONAHA.120.047419","article-title":"Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis?","volume":"141","author":"Campbell","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jaci.2020.07.001_bib107","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01753-18","article-title":"Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis","volume":"9","author":"Gralinski","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.jaci.2020.07.001_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in Covid-19: possible mechanisms of action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2020.07.001_bib109","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"Bloch","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2020.07.001_bib110","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Soo","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaci.2020.07.001_bib111","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jaci.2020.07.001_bib112","doi-asserted-by":"crossref","unstructured":"Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review [published online ahead of print May 1, 2020]. J Med Virol. https:\/\/doi.org\/10.1002\/jmv.25961.","DOI":"10.1002\/jmv.25961"},{"key":"10.1016\/j.jaci.2020.07.001_bib113","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaci.2020.07.001_bib114","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2020.07.001_bib115","doi-asserted-by":"crossref","unstructured":"Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et\u00a0al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial [published online ahead of print June 3, 2020]. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.10044.","DOI":"10.1001\/jama.2020.10044"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674920309593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674920309593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:25:01Z","timestamp":1758792301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674920309593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0091674920309593"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2020.07.001","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2020.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}